FDA publishes roadmap to reducing animal testing in preclinical safety studies
In April 2025, the US Food and Drug Administration (FDA) announced plans to phase out animal testing requirements for development of monoclonal antibodies (mAbs) and other drugs, and instead rely on human-relevant methods, such as in silico and in vitro human-based systems, for safety testing. This release marked the Agency’s first public step towards implementing […]
